Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report) has earned an average recommendation of “Moderate Buy” from the twenty analysts that are currently covering the stock, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $163.4444.
NBIX has been the subject of a number of recent analyst reports. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Neurocrine Biosciences in a research note on Wednesday, October 8th. Piper Sandler lifted their price target on shares of Neurocrine Biosciences from $154.00 to $175.00 and gave the stock an “overweight” rating in a research note on Thursday, July 31st. Needham & Company LLC lifted their price target on shares of Neurocrine Biosciences from $161.00 to $170.00 and gave the stock a “buy” rating in a research note on Monday, September 22nd. Royal Bank Of Canada lifted their price target on shares of Neurocrine Biosciences from $144.00 to $149.00 and gave the stock an “outperform” rating in a research note on Friday, September 5th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Neurocrine Biosciences from $140.00 to $145.00 and gave the company a “neutral” rating in a report on Thursday, July 31st.
View Our Latest Report on Neurocrine Biosciences
Insiders Place Their Bets
Institutional Investors Weigh In On Neurocrine Biosciences
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Dodge & Cox lifted its holdings in Neurocrine Biosciences by 0.6% during the 2nd quarter. Dodge & Cox now owns 5,566,814 shares of the company’s stock valued at $699,693,000 after buying an additional 32,190 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in Neurocrine Biosciences by 59.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 4,261,747 shares of the company’s stock valued at $535,659,000 after buying an additional 1,590,749 shares in the last quarter. Wellington Management Group LLP raised its holdings in shares of Neurocrine Biosciences by 44.0% in the 1st quarter. Wellington Management Group LLP now owns 2,097,981 shares of the company’s stock valued at $232,037,000 after purchasing an additional 640,556 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of Neurocrine Biosciences by 3.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,539,601 shares of the company’s stock valued at $170,281,000 after purchasing an additional 49,088 shares in the last quarter. Finally, AQR Capital Management LLC raised its holdings in shares of Neurocrine Biosciences by 40.5% in the 2nd quarter. AQR Capital Management LLC now owns 1,510,015 shares of the company’s stock valued at $189,794,000 after purchasing an additional 435,385 shares in the last quarter. Institutional investors own 92.59% of the company’s stock.
Neurocrine Biosciences Trading Down 0.2%
NBIX stock opened at $137.52 on Friday. Neurocrine Biosciences has a 12 month low of $84.23 and a 12 month high of $154.61. The company has a 50-day moving average price of $138.35 and a 200 day moving average price of $125.73. The stock has a market cap of $13.64 billion, a PE ratio of 40.69, a P/E/G ratio of 0.99 and a beta of 0.21.
Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The company reported $1.06 EPS for the quarter, topping analysts’ consensus estimates of $0.98 by $0.08. Neurocrine Biosciences had a net margin of 13.88% and a return on equity of 13.22%. The firm had revenue of $687.50 million during the quarter, compared to analysts’ expectations of $653.09 million. During the same period in the previous year, the company earned $1.63 EPS. The firm’s revenue for the quarter was up 16.5% compared to the same quarter last year. Sell-side analysts forecast that Neurocrine Biosciences will post 4.28 EPS for the current year.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
See Also
- Five stocks we like better than Neurocrine Biosciences
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Salesforce’s Long-Awaited Inflection is Here: Rally On!
- How to Short a Stock in 5 Easy Steps
- Rocket Lab USA Receives Wall Street Validation: Time to Buy?
- What is the MACD Indicator and How to Use it in Your Trading
- Archer Buys Rival’s Patent Treasure Trove in Strategic Move
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.